LIXTE Biotechnology Doubles Ovarian Cancer Trial Enrollment for LB-100 Lead Compound
LIXTE Biotechnology has doubled patient enrollment in its clear cell ovarian cancer trial for LB-100, expanding the study to evaluate efficacy in combination with chemotherapy. The company is also broadening clinical investigations to include metastatic colon cancer, leveraging LB-100’s potential to sensitize tumors and enhance immune response.
1. Clinical Trial Expansion in Ovarian Cancer
LIXTE Biotechnology has doubled the enrollment target in its ongoing clear cell ovarian carcinoma trial, effectively increasing the study size to assess LB-100’s efficacy when combined with standard chemotherapy. This expansion aims to generate more robust safety and response data in a patient population with limited treatment options.
2. Broadening to Metastatic Colon Cancer
The company has extended its clinical program to include metastatic colon cancer, initiating or expanding cohorts to evaluate LB-100’s ability to sensitize colon tumors to existing therapies. This strategic move addresses a high-need area where improved response rates could significantly impact patient outcomes.
3. LB-100 Mechanism and Next Steps
LB-100 is designed to sensitize cancer cells to chemotherapy and potentially boost immune system activity, offering a complementary approach to current treatments. LIXTE plans to review interim safety and efficacy results from the expanded cohorts later this year and will explore optimal combination regimens before progressing to later-stage trials.